Kirurgian vastuualue

Julkaisut 2013
Publications 2013

Lisätietoja julkaisusta saa klikkaamalla sen numeroa.
For full details, please click the number in front of the publication.

1 Armin AL Olama a et al. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease.
2 Eeles R et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array.
3 Hakala T et al. A core needle biopsy provides more malignancy-specific results than fine-needle aspiration biopsy in thyroid nodules suspicious for malignancy.
4 Heervä E et al. Neurofibromatosis 1-related osteopenia often progresses to osteoporosis in 12 years.
5 Häkkinen M et al. Analysis of free, mono- and diacetylated polyamines from human urine by LC-MS/MS.
6 Hämäläinen M et al. Dexamethasone-eluting Vascular Stents.
7 Kellokumpu-Lehtinen P, Tammela T. Uusilla lääkkeillä parempaa hoitoa eturauhassyöpään.
8 Kilpeläinen T et al. Prostate cancer mortality in the Finnish randomized screening trial.
9 Kleber ME et al. Genome-Wide Association Study Identifies 3 Genomic Loci Significantly Associated With Serum Levels of Homoarginine: The AtheroRemo Consortium.
10 Kosola J et al. Elevated concentration of oxidized LDL together with poor cardiorespiratory and abdominal muscle fitness predicts metabolic syndrome in young men.
11 Kranse R et al. Excess all-cause mortality in the evaluation of a screening trial to account for selective participation.
12 Laitinen V et al. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.
13 Laukontaus S et al. Onko vatsa-aortan aneurysman seulontaan aihetta Suomessa?
14 Lehmusvaara S et al. Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.
15 Leinonen KA et al. Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer.
16 Linnakoski I et al. Comparison of above-the-knee prosthetic femoro-popliteal bypass versus percutaneous transluminal angioplasty and stenting for treatment of occlusive superficial femoral artery disease.
17 Liuhanen S et al. Indirect measurement of the vascular endothelial glycocalyx layer thickness in human submucosal capillaries with a plug-in for ImageJ.
18 Markus HS et al. Evidence HDAC9 genetic variant associated with ischemic stroke increases risk via promoting carotid atherosclerosis.
19 Melkas S et al. Aivojen pienten suonten tauti.
20 Murtola TJ et al. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5a-reductase inhibitors and alpha-blockers.
21 Mäkelä KM et al. Genome-wide association study pinpoints a new functional apolipoprotein B variant influencing oxidized low-density lipoprotein levels but not cardiovascular events: AtheroRemo Consortium.
22 Nurminen R et al. Fine mapping of 11q13.5 identifies regions associated with prostate cancer and prostate cancer death.
23 Oksala N et al. Association of Neuroimmune Guidance Cue Netrin-1 and Its Chemorepulsive Receptor UNC5B With Atherosclerotic Plaque Expression Signatures and Stability in Human(s): Tampere Vascular Study (TVS).
24 Oksala N et al. Complementary prediction of cardiovascular events by estimated apo- and lipoprotein concentrations in the working age population. The Health 2000 Study.
25 Pöyhönen A et al. Empirical evaluation of grouping of lower urinary tract symptoms: principal component analysis of Tampere Ageing Male Urological Study data.
26 Raitoharju E et al. MicroRNAs in the atherosclerotic plaque.
27 Raitoharju E et al. A comparison of the accuracy of Illumina HumanHT-12 v3 Expression BeadChip and TaqMan qRT-PCR gene expression results in patient samples from the Tampere Vascular Study.
28 Rantanen T et al. CIP2A expression and prognostic role in patients with esophageal adenocarcinoma.
29 Rantanen T et al. Reflux symptoms and side effects among patients with gastroesophageal reflux disease at baseline, during treatment with PPIs, and after Nissen fundoplication.
30 Renko J et al. Bacterial DNA signatures in carotid atherosclerosis represent both commensals and pathogens of skin origin.
31 Saarinen J. Laskimoperäinen turvotus.
32 Salonen A et al. Reply from Authors re: Nicolas Mottet. Intermittent Androgen Deprivation in Prostate Cancer: Is Everything So Clear? Eur Urol 2013;63:121-2 Intermittent Androgen Deprivation in Advanced Prostate Cancer: An Optional Treatment Regimen.
33 Salonen AJ et al. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects.
34 Salonen AJ et al. Reply from Autors re: Nicolas Mottet: Intermittent Androgen-deprivation in Prostate Cancer.
35 Schröder F et al. Reply from Authors re: Behfar Ehdaie, Karim A Touijer. 5-Alpha reductase inhibitors in prostate cancer.
36 Schröder F et al. Dutasteride treatment over 2 years delays prostate-specific antigen progression in patients with biochemical failure after radical therapy for prostate cancer: results from the randomised, placebo-controlled Avodart After ...
37 Sciarra A et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials.
38 Sibolt G et al. Post-stroke depression and depression-executive dysfunction syndrome are associated with recurrence of ischaemic stroke.
39 Sibolt G et al. Poststroke dementia is associated with recurrent ischaemic stroke.
40 Simpson C et al. Genetic heterogeneity in Finnish hereditary prostate cancer using ordered subset analysis.
41 Suominen V et al. Fenestrated and chimney endografts for juxtarenal aneurysms: early and midterm results.
42 Tammela TLJ. Editorial comment: Treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.
43 van Leeuwen Pj et al. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
44 Vasarainen H et al. Effects of prostate cancer screening on health-related quality of life: results of the Finnish arm of the European randomized screening trial (ERSPC).
45 Vaughan C et al. Impact of obesity on urinary storage symptoms: results from the FINNO study.
46 Veitonmäki T et al. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level.
47 Venojärvi M et al. Stress proteins and heat shock proteins role in muscle building and sports nutrition.
48 Xu J et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG).
49 Yli-Hemminki TH et al. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.

Julkaisutietokanta 19.1.2016 Publications Data Base 19.1.2016